Results 1 to 10 of about 770 (112)
Lupus anticoagulant in patients with COVID-19: A review [PDF]
Journal of Preventive Epidemiology, 2021 Introduction: Coronavirus disease 2019 (COVID-19) is characterized by a pro-coagulant state that can lead to fatal thromboembolic events. A high prevalence of lupus anticoagulant has been shown in several studies that may at least partially explain the ...
Milad Nazari Sabet +2 more
doaj +1 more source
Massive thrombosis and phlegmasia cerulea dolens while taking rivaroxaban: case report and review [PDF]
Jornal Vascular Brasileiro, 2021 Our study describes a fatal case of phlegmasia cerulea dolens and massive venous thrombosis in a patient taking rivaroxaban regularly to treat cerebral venous sinus thrombosis. Blood tests samples were positive for lupus anticoagulant.
Diego Chemello +6 more
doaj +1 more source
Lupus Science and Medicine, 2020 Objective Persistent positivity for lupus anticoagulant has been associated with an increased risk of thrombosis among patients with SLE. Persistent positivity is often defined as having two positive assessments separated by more than 90 days.
Laurence S Magder, Mertcan Avci
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2021 On an international scale, guidelines and proposals for lupus anticoagulant detection have been published over the last 20 years, but until now, standardization has not been completely realized. The aim of this study was to evaluate the different ways of
Feng Lu +4 more
doaj +1 more source
TH Open, 2020 Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo +7 more
doaj +1 more source
Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients. [PDF]
PLoS ONE, 2016 The activated partial thromboplastin time (APTT) assay is a basic hemostatic assay based on the time it takes for clots to form in plasma samples after the addition of calcium chloride. It is used to screen for various coagulation disorders.
Takayoshi Tokutake +10 more
doaj +1 more source
Experimental Biology and Medicine, 1984 Lupus-like anticoagulant (LLAC) is the term used to identify an acquired inhibitor (1) of blood coagulation, first described by Conley and Hartmann in patients with systemic lupus erythematosus (SLE) (2). A circulating “lupus-like” anticoagulant has been detected in 5-10% of all SLE patients.
N, Perico, F, Pusineri, G, Remuzzi
openaire +2 more sources
Anaesthesia, 1987 Summary Circulating lupus anticoagulant occurs in 5–37% of all patients with systemic lupus erythematosus. Its occurrence is not restricted to collagen vascular disease states. Lupus anticoagulant causes a prolongation of certain laboratory coagulation studies yet it is associated in vivo with a history of systemic intravascular ...
A M, Malinow +4 more
+8 more sources
Transmission of lupus anticoagulant by allogeneic stem cell transplantation
Revista Brasileira de Hematologia e Hemoterapia, 2014 Passive transmission of autoimmune diseases by allogeneic stem cell transplantation is rare and is ascribed to passive transfer of memory B-cells from donor to recipient. We hereby report a case of transmission of an asymptomatic lupus anticoagulant from
Mira Romany Massoud +5 more
doaj +1 more source
Thrombosis Journal, 2006 Background Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with
Wisløff Finn +3 more
doaj +1 more source